WO2000000600A3 - Lentiviral vectors, comprising modified major donor splice sites and major packaging signals - Google Patents

Lentiviral vectors, comprising modified major donor splice sites and major packaging signals Download PDF

Info

Publication number
WO2000000600A3
WO2000000600A3 PCT/US1999/011516 US9911516W WO0000600A3 WO 2000000600 A3 WO2000000600 A3 WO 2000000600A3 US 9911516 W US9911516 W US 9911516W WO 0000600 A3 WO0000600 A3 WO 0000600A3
Authority
WO
WIPO (PCT)
Prior art keywords
vector
major
packaging
expression
functional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/011516
Other languages
French (fr)
Other versions
WO2000000600A2 (en
Inventor
Lung-Ji Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/935,312 external-priority patent/US6207455B1/en
Application filed by Individual filed Critical Individual
Priority to AU43126/99A priority Critical patent/AU773015B2/en
Priority to CA002333481A priority patent/CA2333481A1/en
Priority to EP99957641A priority patent/EP1082447A2/en
Publication of WO2000000600A2 publication Critical patent/WO2000000600A2/en
Publication of WO2000000600A3 publication Critical patent/WO2000000600A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A packaging vector comprising a nucleotide sequence encoding Gag and Pol proteins of a reference lentivirus, said packaging vector differing from said reference lentivirus at least in that (a) its major splice donor site is either deleted, or if provided, while functional, differs in sequence from that of said reference lentivirus sufficiently so that said major splice donor site is not a potential site for homologous recombination between said packaging vector and said reference lentivirus, and (b) it lacks a functional major packaging signal, which vector, after introduction into a suitable host cell, is capable of causing such cell, either through expression from said vector alone, or through co-expression from said vector and a second vector providing for expression of a compatible envelope protein, to produce packaging vector particles comprising functional Gag and Pol proteins and having a normal or a pseudotyped envelope, where said particles are free of the RNA form of said packaging vector as a result of (b) above, where said cell, as a result of said expression or co-expression, produces particles encapsulating the RNA form of a transducing vector possessing a compatible and functional packaging signal if said transducing vector is introduced into said cell.
PCT/US1999/011516 1997-09-22 1999-05-26 Lentiviral vectors, comprising modified major donor splice sites and major packaging signals Ceased WO2000000600A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU43126/99A AU773015B2 (en) 1998-05-26 1999-05-26 Lentiviral vectors
CA002333481A CA2333481A1 (en) 1998-05-26 1999-05-26 Lentiviral vectors, comprising modified major donor splice sites and major packaging signals
EP99957641A EP1082447A2 (en) 1998-05-26 1999-05-26 Lentiviral vectors, comprising modified major donor splice sites and major packaging singals

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/935,312 US6207455B1 (en) 1997-05-01 1997-09-22 Lentiviral vectors
US8663598P 1998-05-26 1998-05-26
US60/086,635 1998-05-26

Publications (2)

Publication Number Publication Date
WO2000000600A2 WO2000000600A2 (en) 2000-01-06
WO2000000600A3 true WO2000000600A3 (en) 2000-10-12

Family

ID=26774974

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/011516 Ceased WO2000000600A2 (en) 1997-09-22 1999-05-26 Lentiviral vectors, comprising modified major donor splice sites and major packaging signals

Country Status (1)

Country Link
WO (1) WO2000000600A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2698222B2 (en) * 1991-03-25 1998-01-19 シャープ株式会社 Sample hold circuit
EP1188835A4 (en) * 1999-06-22 2004-07-07 Dnavec Research Inc A vector for the expression of two foreign genes
CA2388301C (en) 1999-10-22 2011-01-04 Aventis Pasteur Limited Modified gp100 and uses thereof
WO2001083730A2 (en) * 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant lentiviral vectors pseudotyped in envelopes containing filovirus binding domains
US7851212B2 (en) 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
CA2468861C (en) 2001-12-05 2012-06-12 The Regents Of The University Of California Robotic microscopy systems
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
GB0325379D0 (en) * 2003-10-30 2003-12-03 Oxford Biomedica Ltd Vectors
US8765462B2 (en) 2007-05-04 2014-07-01 University Health Network IL-12 immunotherapy for cancer
WO2009049350A1 (en) 2007-10-15 2009-04-23 The University Of Queensland Expression system for modulating an immune response
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
CN108601951B (en) 2015-12-09 2022-11-22 金港医疗(澳大利亚)私人有限公司 Immunomodulatory compositions for treatment
US11285191B2 (en) 2016-07-26 2022-03-29 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Immunostimulatory compositions and uses therefor
WO2020059848A1 (en) * 2018-09-20 2020-03-26 国立大学法人東京医科歯科大学 Method for enhancing lentivirus vector production
US20240052366A1 (en) * 2020-02-13 2024-02-15 Oxford Biomedica (Uk) Limited Production of Lentiviral Vectors
TWI758171B (en) 2021-04-28 2022-03-11 沛爾生技醫藥股份有限公司 Lentivirus packaging system and the method of using the same for improving lentivirus production in a host cell
CN115247190B (en) * 2021-04-28 2024-06-18 沛尔生技医药股份有限公司 Lentivirus packaging system, lentivirus produced therefrom, cells transduced by the lentivirus, and applications thereof
CN113789345A (en) * 2021-08-11 2021-12-14 康美润源(北京)生物技术有限公司 Kit for detecting replication-competent lentivirus (RCL) and application thereof
CN114107396B (en) * 2021-11-26 2024-02-02 和元智造(上海)基因技术有限公司 Lentiviral vector, system and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002805A2 (en) * 1989-08-18 1991-03-07 Viagene, Inc. Recombinant retroviruses delivering vector constructs to target cells
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
WO1999004026A2 (en) * 1997-07-18 1999-01-28 Chiron Corporation Lentiviral vectors
WO1999019501A1 (en) * 1997-10-14 1999-04-22 Institute For Vaccine Development Non-integrating dna vector of retroviral origin having high-protein expression, and secreted immunogenic antigens

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
WO1991002805A2 (en) * 1989-08-18 1991-03-07 Viagene, Inc. Recombinant retroviruses delivering vector constructs to target cells
WO1999004026A2 (en) * 1997-07-18 1999-01-28 Chiron Corporation Lentiviral vectors
WO1999019501A1 (en) * 1997-10-14 1999-04-22 Institute For Vaccine Development Non-integrating dna vector of retroviral origin having high-protein expression, and secreted immunogenic antigens

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
AMENDT B. A. ET AL.: "Presence of Negative and Positive cis-Acting RNA Splicing Elements eihtin and Flankin the Frist tat Coding Exon of Human Immunodificiency virus Type 1", MOLECULAR AND CELLULAR BIOLOGY, vol. 14, no. 6, June 1994 (1994-06-01), pages 3960 - 3969, XP002140661 *
ASHE MP. ET AL.: "Poly(A) site selection in the HIV-1 provirus: inhibition of promoter-proximal polyadenylation by the downstream major splice donor site.", GENES DEV 1995 DEC 1;9(23):3008-25, XP000915765 *
ASHE MP. ET AL.: "The HIV-1 5' LTR poly(A) site is inactivated by U1 snRNP interaction with the downstream major splice donor site.", EMBO J 1997 SEP 15;16(18):5752-63, XP002140099 *
BORG KT. ET AL.: "Activation of a cryptic splice donor in human immunodeficiency virus type-1.", J BIOMED SCI 1999 JAN;6(1):45-52, XP002140101 *
BORG KT. ET AL.: "Involvement of human immunodeficiency virus type-1 splice sites in the cytoplasmic accumulation of viral RNA.", VIROLOGY 1997 SEP 15;236(1):95-103, XP000910228 *
CHANG DD. ET AL.: "Messenger RNA transport and HIV rev regulation.", SCIENCE 1990 AUG 10;249(4969):614-5, XP000910225 *
CUI YAN ET AL: "Contributions of viral splice sites and cis-regulatory elements to lentivirus vector function.", JOURNAL OF VIROLOGY JULY, 1999, vol. 73, no. 7, July 1999 (1999-07-01), pages 6171 - 6176, XP000882588, ISSN: 0022-538X *
DULL T ET AL: "A third-gneration lentivirus vector with a conditional packaging system", JOURNAL OF VIROLOGY,US,THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 72, no. 11, November 1998 (1998-11-01), pages 8463 - 8471-8471, XP002117829, ISSN: 0022-538X *
IWAKUMA T ET AL: "SELF-INACTIVATING LENTIVIRAL VECTORS WITH U3 AND U5 MODIFICATIONS", VIROLOGY,US,ACADEMIC PRESS,ORLANDO, vol. 261, no. 1, 1999, pages 120 - 132, XP000882897, ISSN: 0042-6822 *
MCCANN E. M., ET AL.: "Location of cis-Acting Sgnals Important for RNA Ecapsidation in the leader sequence of human immunodficiency virus type 2", JORUNAL OF VIROLOGY, vol. 71, no. 5, May 1997 (1997-05-01), pages 41334133 - 4137, XP000909426 *

Also Published As

Publication number Publication date
WO2000000600A2 (en) 2000-01-06

Similar Documents

Publication Publication Date Title
WO1999004026A3 (en) Lentiviral vectors
DE69922978D1 (en) TRANSFORMATION SYSTEM IN FILAMENTOUS FUNGICIDES CHRYSOSPORIUM HOST CELLS
NZ500740A (en) Recombinant lentivirus-based gene transfer vectors comprising 3 vectors from Equine Infectious Anemia Virus (EIAV)
CA2015077A1 (en) A yeast cell of the genus schwanniomyces
EP0370458A3 (en) Synthetic DNA derived recombinant HIV-1 antigens
EP0175360A3 (en) Peptide antibodies and their use in detecting oncogene products
AU4712397A (en) Lentiviral vectors
EP1798239A3 (en) G-protein coupled receptors and uses therefor
WO1996034107A3 (en) Antiviral proteins, dna coding sequences therefor, and uses thereof
WO2000073316A3 (en) Virus immunologic determinants
WO1989007136A3 (en) Modified hepatocytes and uses therefor
AU6860396A (en) Purified coprinus laccases and nucleic acids encoding same
WO2002002783A3 (en) Expression vectors
AU3192889A (en) T cell activation markers
CZ20002008A3 (en) Hydrophobic modified preparations and modification methods
IL148785A0 (en) Vectors and methods for recombinant protein expression
AU3802595A (en) Tripeptidyl aminopeptidase
WO1999009179A3 (en) Antigen constructs useful in the detection and differentiation of antibodies to hiv
WO1996007739A3 (en) Interleukin-1 type 3 receptors
WO1993017118A3 (en) Defective packaging non-oncoviral vectors based on mpmv and hiv
AU6991994A (en) Prostaglandin receptor ep3 and dna encoding it
DE69612660D1 (en) PSEUDOTYPIZED RETROVIRAL VECTORS
EP0177814A3 (en) Peptide antibodies and their use in detecting oncogene products
WO1990007000A3 (en) Nucleotides encoding human b1, 4-galactosyltransferase and uses thereof
EP0293079A3 (en) Chlamydia vaccine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: KR

ENP Entry into the national phase

Ref document number: 2333481

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 43126/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999957641

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999957641

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 43126/99

Country of ref document: AU